Axicabtagene Ciloleucel Demonstrates High Response Rate in Relapsed/Refractory Large B-cell Lymphoma
September 22nd 2023Axicabtagene ciloleucel achieved a complete metabolic response of 71% at 3 months versus 12% expected with standard of care among transplant ineligible patients with relapsed/refractory large B-cell lymphoma.
Read More
Study: Shared Decision-Making in Cardiovascular Health is Infrequently Utilized, Despite Benefits
September 19th 2023Shared decision-making can be better incorporated into cardiovascular care guidelines by including decision aids, such as informational flyers or online tools to help patients.
Read More
Study Suggests Base-Edited T Cells Could Minimize Immunotherapy Complications in Leukemia Treatment
September 14th 2023The use of base editing to generate universal, off-the-shelf CAR T cells is a promising approach for relapsed leukemia, with potential implications for the future of gene therapy.
Read More
Bispecific Antibodies Achieve High Response Rates, Tolerable Adverse Effects in Multiple Myeloma
September 13th 2023Bispecific antibodies have offered a new treatment approach in relapsed/refractory multiple myeloma, with promising results in preclinical studies for multiple cancers and hematological malignancies.
Read More
Point-of-Care Test Reagents Could Aid Risk Assessment for In-Home Care of Older Adults
September 8th 2023In addition to improving risk evaluation in older adults at home, point-of-care testing may help clinicians manage patients with dementia who cannot communicate and those living in depopulated areas.
Read More
Data Show Durable Efficacy With Repotrectinib for Locally Advanced or Metastatic ROS1-Positive NSCLC
August 18th 2023Based on results from a trial of repotrectinib in patients with ROS1-positive locally advanced or metastatic non-small cell lung cancer, the FDA accepted the New Drug Application and set a Prescription Drug User Fee Act goal date of November 27, 2023.
Read More